First, the main control system consists of the German "Siemens" PLC and the Japanese "Pro-face" GP series color touch screen. The control system has a complete alarm function and intelligent control logic. It has high precision, small deviation, Chinese prompt, direct input, output, display and control temperature, simple operation and other functions. The control system has been independently developed and put into use by our team of senior engineers, with independent intellectual property rights.
Second, the system can be used independently of the high temperature box and the low temperature box, and can also be used for repeated impact tests of high temperature and low temperature. Make the test box a three-box.
Third, the main features:
1. Perfect safety protection device.
1) Studio over temperature protection.
2) Power phase loss, phase protection.
3) Over-current protection of the upper and lower blast motor.
4) Upper and lower box heating short circuit protection.
5) Refrigerator overpressure and overload protection 6) Refrigerator oil shortage protection (when the refrigerator is equipped with oil pump)
7) Compressor water shortage protection (when water is cold)
8) Upper and lower door closing protection 2. Concise and practical man-machine picture.
High temperature test or low temperature test only need to set the exposure temperature and exposure time.
High and low temperature impact test also needs to set the preset temperature and the number of cycles.
The concise and practical man-machine screen allows the user to operate freely without having to read the manual. The simplified operation process allows the user to set the required parameters for long-term reliable operation. The intelligent PID control system can realize high-precision control only by adjusting the parameters at an initial stage.
Palbociclib is a drug for the treatment of ER-positive and HER2-negative breast cancer developed by Pfizer. It is a selective inhibitor of the cyclin-dependent kinases CDK4 and CDK6.
It was reviewed and approved under the Food and Drug Administration`s (FDA) accelerated Priority Review and Breakthrough Therapy designation programs on February 3, 2015 as a treatment (in combination with letrozole) for patients with estrogen receptor positive advanced breast cancer.
We produce a series of complete intermediates for Palbociclib, intermediate I (CAS No. 571188-59-5), intermediate II (CAS No. 1013916-37-4) and intermediate III (CAS No. 1016636-76-2) etc.
All of our products are with stable production and strict quality control, making sure your experience with Sunshine Biotech is always enriching, satisfying and fulfilling.
Palbociclib Intermediates,Cas 571188-59-5,Cas 1013916-37-4,Cas 1016636-76-2
Nanjing Sunshine Biotech Co., Ltd , https://www.sunshine-bio.com